Compare NPK & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | INBX |
|---|---|---|
| Founded | 1905 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.1M | 999.7M |
| IPO Year | 1994 | 2024 |
| Metric | NPK | INBX |
|---|---|---|
| Price | $140.67 | $133.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | 59.7K | ★ 486.3K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $503,524,000.00 | $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $137.87 | ★ N/A |
| Revenue Growth | 29.70 | ★ 550.00 |
| 52 Week Low | $82.67 | $12.80 |
| 52 Week High | $149.86 | $155.29 |
| Indicator | NPK | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 52.87 | 66.58 |
| Support Level | $129.58 | $69.30 |
| Resistance Level | $148.70 | $155.29 |
| Average True Range (ATR) | 6.22 | 13.75 |
| MACD | -0.44 | 0.62 |
| Stochastic Oscillator | 70.91 | 69.23 |
National Presto Industries Inc has an eclectic product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments namely Defense, Housewares/Small Appliance, and Safety. The defense segment which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases; performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances; the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.